all prices
| price | high | low | % | ||
|---|---|---|---|---|---|
| Dow Jones | 28229 | 28694 | 28030 | -2.67 % | |
| S&P500 | 3258 | 3305 | 3232 | -2.44 % | |
| Nasdaq 100 | 9181 | 9319 | 9046 | -2.85 % | |
| Euro Stoxx 50 | 3653 | 3752 | 3631 | -3.67 % | |
| FTSE 100 | 7147 | 7340 | 7115 | -3.52 % | |
| CAC40 | 5791 | 5921 | 5764 | -3.8 % | |
| DAX | 13058 | 13404 | 12983 | -3.65 % | |
| Hong Kong HSI | 26499 | 27127 | 26380 | -3.05 % | |
| Nikkei 225 | 22346 | 22866 | 22181 | -3.72 % |
Live stock markets prices
- 15 min
- 1H
- 4H
- Daily
| Dow Jones | 28232 | -2.66% |
|---|---|---|
| S&P500 | 3258 | -2.44% |
| Nasdaq 100 | 9177 | -2.89% |
| FTSE 100 | 7147 | -3.52% |
| CAC40 | 5788 | -3.85% |
|---|---|---|
| Nikkei 225 | 22341 | -3.74% |
| Euro Stoxx 50 | 3652 | -3.7% |
| DAX | 13056 | -3.66% |
Latest news
| Director/PDMR Shareholding |
| DFDS ANNUAL REPORT 2019 |
| Innovation Pharmaceuticals Submits Material Transfer Agreement to Study Lead Defensin Mimetic Brilacidin for Coronavirus (COVID-19) |
| Nymox Announces New Peer Review Publication of Prostate Cancer Fexapotide Clinical Trial Results in World Journal of Urology |
| Tamino Minerals, Inc. has a Geologic Report on its Property soon to be NI 43-101 Report and Prepares for Authorized Shares Reduction |
| On a Mission to Protect Our Planet’s Water: Seventh Generation Launches New Personal Care Line |
| Coyote Expands CoyoteGO® Digital Freight Platform to Better Connect Shippers and Carriers On-Demand Across All Devices |
| Rafarma Has Officially Begun Research Programs with Khon Kaen University in Thailand |
| NORBIT – Key information relating to the cash dividend to be paid by NORBIT ASA |
| Generex Congratulates their Shareholders as FINRA has Officially Posted the Approval of the Generex Corporate Action and Payment of the Generex and NuGenerex Immuno-Oncology Stock Dividends on Monday, February 24, 2020 |
| MariMed Harvests its First Cannabis Crop in Massachusetts Amidst State-Wide Flower Shortage |
| Update: Peeled Snacks Gearing Up for New Products, Market Expansion on Major Funding Announcement |
| Shawcor Announces Contract Awards for the Sangomar and Baltic Pipe Projects |
| Oxford Immunotec Schedules Fourth Quarter and Full Year 2019 Earnings Release and Conference Call for March 2, 2020 |
| Telos Corporation Nationally Designated as One of the Best Workplaces for Commuters in 2020 |
| Alliance Trust PLC - Net Asset Value |
| Middlefield Canadian Income PCC: Net Asset Value(s) |
| ClearOne Seeks Order Holding Shure in Contempt for Marketing and Selling the MXA910W-A in Violation of 2019 Preliminary Injunction |
| Capital Market Laboratories (CMLviz) Interviews Talend (TLND) CEO and CFO – ‘The opportunity is massive, and we want to get it right’ |
| ORYZON Reports Financial Results and Corporate Update for 4th Quarter and Year Ended December 31, 2019 |
Director/PDMR Shareholding
24th February 2020
PayPoint plc ("the Company")
As a result of transactions on 24th February 2020 by the PayPoint plc Share Incentive Plan (a HM Revenue & Customs approved all employee share purchase plan), the executive directors and persons discharging management responsibility of the Company have the following interests as a result of their personal participation in the Plan:-
                                              Â
|    | Partnership Shares Purchase Date: 24/02/2020 Share Price: £9.254 | Matching Shares Award Date: 24/02/2020 Share Price: £9.254 | Total number of Partnership, Matching and Dividend Shares held on 24/02/2020 |
| Tim Watkin-Rees | 13 | 13 | 15,493 |
| Jon Marchant | 13 | 13 | 3,081 |
| Katy Wilde | 14 | 14 | 2,408 |
| Lewis Alcraft | 13 | 13 | 6,633 |
| Rachel Kentleton | 13 | 13 | 1,450 |
In accordance with the rules of the Plan the persons named above have been awarded the Matching Shares on the basis of one Matching Share for each Partnership Share.
The beneficial ownership of the Matching Shares will pass to the persons listed above in three years time subject to continued employment and the retention of the underlying Partnership Shares.
Enquiries:
Sarah Carne
Company Secretary
-ends-
DFDS ANNUAL REPORT 2019
COMPANY ANNOUNCEMENT NO. 3/2020
DFDSâ Annual Report for 2019, including the CSR Report for 2019, have now been published and are available from this link:
https://www.dfds.com/en/about/investors/reports-and-presentations
See also attached reports.
Contact
Torben Carlsen, CEO, +45 33 42 32 01
Karina Deacon, CFO, +45 33 42 33 42
Søren Brøndholt Nielsen, IR, +45 33 42 33 59
Gert Jakobsen, Communications, +45 33 42 32 97
Â
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Attachments
Innovation Pharmaceuticals Submits Material Transfer Agreement to Study Lead Defensin Mimetic Brilacidin for Coronavirus (COVID-19)
WAKEFIELD, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (âthe Companyâ), a clinical stage biopharmaceutical company, announced today the Company submitted a Material Transfer Agreement (MTA) with a leading U.S.-based virology laboratory to research its lead defensin mimetic drug candidate, Brilacidin as a potential novel coronavirus treatment. Brilacidin has demonstrated broad and robust antibacterial, anti-inflammatory and immunomodulatory properties in multiple FDA clinical trials in different indications.
Under terms of the agreement, Brilacidinâs potential inhibition of SARS-CoV-2, the virus responsible for COVID-19, is planned to be assessed.
Discussions also are underway with a government-funded virology laboratory in Asia, to assess Brilacidin across a range of RNA viruses. On a related note, the Company has submitted a preliminary summary of Brilacidinâs potential as a novel coronavirus treatment to the Biomedical Advanced Research and Development Authority (BARDA), which is dedicated to rapidly identifying and funding medical countermeasures to the COVID-19 outbreak.
As previously released, and as supported in the academic literature, defensin-based therapeutics represent an attractive potential intervention to combat coronavirus infections given their innate multifaceted immunomodulatory properties. Brilacidin, and other defensin mimetics similar in structure, have been tested against numerous clinical isolates of both gram-positive and gram-negative infectious pathogens, with strong activity exhibited across multiple isolates. Enveloped viruses have also been tested, with moderate activity noted.
The Review Article on coronaviruses linked to below suggests immunomodulators, like Brilacidin, might be promising therapeutic options, acting synergistically when combined with other antivirals.
- Zumia, A., et al. âCoronaviruses - Drug Discovery and Therapeutic Options.â Nat Rev Drug Discov. 2016 May;15(5):327-47. doi: 10.1038/nrd.2015.37. Epub 2016 Feb 12. https://www.nature.com/articles/nrd.2015.37
The underlying theory is that once the viral load is reduced, the bodyâs natural immune responseâpossibly strengthened by Brilacidin administered post-infection as an adjuvant therapyâshould be better able to fight off coronavirus complications. Defensin-based vaccines also have been proposed. Brilacidin, shown in pre-clinical tests to inhibit PDE4/PDE3, might provide added benefit as a result of this particular mechanism by: 1) disrupting viral replication; and 2) enhancing the protective role of natural surfactants in the lung, helping resolve respiratory problems common to the coronavirus.
Should laboratory tests support Brilacidinâs antiviral activity against SARS-CoV-2 (COVID-19), and potentially other RNA viruses, the Company will look to expedite research and clinical development of Brilacidin as a potential antiviral therapy via pharmaceutical partnerships, academic collaborations and government grants.
The current coronavirus (COVID-19) outbreak continues to pose a significant life-threatening risk in China and throughout the rest of the world. Currently, over 79,000 cases have been diagnosed across 29 countries, including the U.S., resulting in nearly 2,600 reported deaths. There are growing signs the global economy is being severely impacted due to this emerging potential pandemic.
If the MTA is concluded, as the Company expects, the drug will be put into queue for testing. There is no assurance made or implied that testing of Brilacidin for any coronavirus will be conducted or successful. The Company will keep shareholders apprised of news related to evaluating Brilacidinâs antiviral properties for potentially treating COVID-19, and other viruses, in addition to its core Brilacidin programs, in Ulcerative Colitis and Oral Mucositis.
Alerts
Sign-up for Innovation Pharmaceuticals email alerts is available at:
http://www.ipharminc.com/email-alerts/
About Innovation Pharmaceuticals
Innovation Pharmaceuticals Inc. (IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious disease, and dermatologic diseases. Brilacidin, a versatile compound with broad therapeutic potential, is in a new chemical class called defensin-mimetics. A Phase 2 trial of Brilacidin as an oral rinse for the prevention of Severe Oral Mucositis (SOM) in patients with Head and Neck Cancer, met its primary and secondary endpoints, including reducing the incidence of SOM. The Company plans to advance Brilacidin oral rinse into Phase 3 development, subject to available financial resources. Positive results were also observed in a Phase 2 Proof-of-Concept trial treating patients locally with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS). Brilacidin for UP/UPS was licensed to Alfasigma S.p.A. in July 2019. A Phase 2b trial of Brilacidin showed a single intravenous dose of the drug delivered comparable outcomes to a seven-day dosing regimen of the FDA-approved blockbuster daptomycin in treating Acute Bacterial Skin and Skin Structure Infection. Kevetrin is a novel anti-cancer drug shown to modulate p53, often referred to as the âGuardian Angel Geneâ due to its crucial role in controlling cell mutations and has successfully completed a Phase 2 trial in Ovarian Cancer. More information is available on the Company website at www.IPharmInc.com.
Forward-Looking Statements: This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning the future execution of a definitive agreement with a global pharmaceutical company and the anticipated terms thereof, our future drug development plans, other statements regarding future product developments, and markets, including with respect to specific indications, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties and assumptions that could cause the Companyâs actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as âanticipates,â âbelieves,â âhopes,â âestimates,â âlooks,â âexpects,â âplans,â âintends,â âgoal,â âpotential,â âmay,â âsuggest,â and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Companyâs need for, and the availability of, substantial capital in the future to fund its operations and research and development; including the amount and timing of the sale of shares of common stock under securities purchase agreements; the fact that the Companyâs licensee(s) may not successfully complete pre-clinical or clinical testing and the Company will not receive milestone payments, or the fact that the Companyâs compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in the Companyâs filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
INVESTOR AND MEDIA CONTACT
Innovation Pharmaceuticals Inc.
Leo Ehrlich
info@ipharminc.comÂ
Nymox Announces New Peer Review Publication of Prostate Cancer Fexapotide Clinical Trial Results in World Journal of Urology
HASBROUCK HEIGHTS, N.J., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that a new peer review report was published today in the World Journal of Urology, documenting the successful long-term clinical trial results after Fexapotide Triflutate treatment for early stage prostate cancer.
This report represents the first publication in the medical literature of multi-year long-term data from a well-powered prospective randomized multi-center clinical trial for a prostate injectable treatment in men targeted to low grade early prostate cancer and showing statistically significant efficacy for a locally targeted molecular injectable treatment.
The new publication is entitled "Prospective Evaluation of Fexapotide Triflutate Injection âTreatment of Grade Group 1 Prostate Cancer: Four Year Resultsâ. The authors are Neal Shore, Myrtle Beach, SC; Steven A. Kaplan, New York, NY; Ronald Tutrone, Baltimore, MD; Richard Levin, Towson, MD; James Bailen, Louisville, KY; Alan Hay, Salem, OR; Susan Kalota, Tucson, AZ; Mohamed Bidair, San Diego, CA; Sheldon Freedman, Las Vegas, NV; Kenneth Goldberg, Lewisville, TX; Frederick Snoy, Albuquerque, NM; Jonathan I. Epstein, Baltimore, MD. The article is available online at https://link.springer.com/article/10.1007/s00345-020-03127-w.   Â
The Fexapotide (FT) study was started in 2012 and enrolled 147 men with localized Gleason Grade 6 T1c prostate cancer at 28 U.S. clinical investigation sites. Patients were followed with clinical and laboratory evaluations and regular periodic prostate biopsies for up to 5 years. Patients randomized to FT were treated with a single one-time targeted injection of FT, either 2.5mg or 15mg. Statistical comparisons were made over time of the proportions of subjects and untreated controls who progressed to higher Gleason grade and/or invasive treatments instituted with prostatectomy, radiotherapy, or chemotherapy. Important clinical highlights from the study include: FT treatment reduced cancer progression (-67.7%) compared to controls (3 years, FT 15mg, p<.02, pooled FT p=.0265) and also reduced (-54.7%) the incidence of surgery, radiotherapy or chemotherapy (4 years, FT 15mg p<.02; pooled FT p=.0374). At 4 years the incidence of surgery, radiotherapy or chemotherapy with increased Gleason grade was significantly reduced (FT 15mg -73.3% p=.0059, pooled FT p=.0064). Results for the high dose (FT 15mg) were superior to the lower dose (FT 2.5mg). Safety data showed no serious adverse events related to FT during the study.
The current recommended standard of care for these patients is active surveillance: patients are monitored carefully over time to determine if and when the cancer becomes more advanced and thus will require more aggressive treatment, like radiation therapy or surgery.
Dr. Neal Shore, lead author of the report, said âThe study results demonstrate data in a large multi-center clinical trial of men treated with transrectal ultrasound guided FT for early stage, low risk prostate cancers, which suggest an effective result for reducing histopathologic progression, as evidenced by repeated biopsies over time, while also demonstrating a favorable safety profile. This study presents long-term FT data which supports its efficacy for avoidance of biologic progression in an active surveillance prostate cancer population. A therapy to optimize the success of an active surveillance strategy is a welcomed advance for these patients."
Dr Steven Kaplan, Professor of Urology and Director of the Benign Urologic Diseases and The Men's Health Program at Icahn School of Medicine at Mount Sinai, New York, and a co-author of the report said, "This study reports the long-term data from a prospective study of an injectable for localized Grade Group 1 prostate cancer -- which is the first time this has been accomplished for a very common problem in men. Regulatory approval of Fexapotide Triflutate (FT) will be a very important treatment adjunct for countless men with this problem.â
The FT treatments were administered in a urology office setting without anesthesia or sedation, consisting of a single relatively painless transrectal injection into the area of the prostate cancer. The percentage of patients with surgery or radiotherapy with Gleason grade progression was reduced by 73.3% in patients treated with a single injection of FT 15mg and by 62.6% in pooled (high and low dose FT groups combined) FT patients compared to controls.
Dr. Jonathan Epstein a co-author and researcher involved in the study, stated "Although more and more men are electing active surveillance for low grade prostate cancer, approximately 25-35% will show increased grade on follow-up biopsy which typically leads to definitive therapy. In this study, Fexapotide Triflutate decreased the risk of upgrading on follow-up biopsy enabling men to stay on active surveillance. Even if Fexapotide Triflutate enables men to stay on active surveillance longer before they eventually experience upgrading, there would be a significant benefit for men to delay the onset of side effects associated with therapy and in the interim enjoy a better quality of life. Future studies are needed to expand the criteria for study of Fexapotide Triflutate to include men with large volume Grade Group 1 disease and possibly men with low volume, low percent pattern 4 Grade Group 2 cancer. Identifying the ideal candidates for Fexapotide Triflutate also factoring in multiparametric MRI findings remains to be determined."
FT is a pro-apoptotic proprietary drug which promotes natural programmed cell death (apoptosis) in prostatic glandular cells which compose the prostate cancer. FT has been safely administered to men in clinical trials in the U.S. involving over 1700 patients and controls treated for BPH or prostate cancer. FT has completed Phase 3 studies for BPH and further studies of FT for prostate cancer are planned in the near future.
For further detailed information about the published study please refer to the new report online at the World Journal of Urology.
For more information please contact info@nymox.com or 800-936-9669.
Forward Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of Fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for Fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox's regulatory filings, Nymox's substantial dependence on Fexapotide, Nymox's commercialization plans and efforts and other matters that could affect the availability or commercial potential of Fexapotide. Nymox undertakes no obligation to update or revise any forward looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox's current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2018, and its Quarterly Reports.
For Further Information Contact:
Erik Danielsen
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com
Â
Tamino Minerals, Inc. has a Geologic Report on its Property soon to be NI 43-101 Report and Prepares for Authorized Shares Reduction
MONTREAL, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Tamino Minerals, Inc. ("Tamino" or the "Company") (OTC Markets: TINO), as mentioned before the Company has prepared a Geologic Report on its El Volcan Property.
Some of our most important investors have been requesting information on this specific which we intend to address professionally. It is very important to mention that to convince a Professional Geologist to write a NI 43-101 Report the company must have a Property of Merit. A synonym of a Property of Merit is an Exploration Target. Having an exploration basically means that the company has a recommendation by a talented geologist certified to make such recommendations and predicting a successful outcome.
Colloquially speaking that means that the property has a certain amount of reconnaissance work that would certify that economic amounts of Gold, Silver, Copper, Zinc or Lead could be found. Other minerals of value could be found in mining exploration projects, but on this one we believe that this is the way to start. This is the first step far from finalizing a Bankable Feasibility Study but a great beginning for a company like ours. We invite you to participate and invest in order to develop this asset.
The company is currently working on the logistical aspects required to implement the Geologic Report. The Company will be ready to present its NI 43-101 Report soon as we proceed to prepare all necessary logistical aspects.
We are also working on other acquisitions. During the last several years the company has spotted several interesting opportunities located in various places within Mexico and other countries.
So far, the Company hasnât diluted a single share. The company currently has 149,811,161 common shares outstanding in the Float.
The Company is projecting that it will lower the Authorized Shares from 1 Billion Common Shares to 650 Million Common Shares.
The company will make further announcements on its other projects as progress is made.
TAMINO MINERALS, INC.
TAMINO MINERALS INC. is exploring for gold and other mineral deposits within a prolific Gold producing State, Sonora. Under SEC Fair Disclosure Guidelines, persons interested in Tamino Minerals can expect disclosures and updates at OTC Markets, the companyâs website, www.taminominerals.ca
Twitter: www.Twitter.com/TaminoMinerals
Facebook:Â Â www.facebook.com/taminominerals
Instagram: www.instagram.com/taminomineralsÂ
Linkedin: www.linkedin.com/company/taminomineralsÂ
and YouTube:Â Â http://bit.ly/33nPS9n
On behalf of the Board,
Pedro Villagran-Garcia, President & CEO
Tamino Minerals, Inc.
For further information, please contact the Company at 1-514-432-7746 or by email at info@taminominerals.ca
Forward Looking Statements
Certain information contained in this press release, including any information as to our strategy, plans or future financial or operating performance and other statements that express management's expectations or estimates of future performance, constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical fact, are forward-looking statements. The words "believe," "expect," "will," "anticipate," "contemplate," "target," "plan," "continue," "budget," "may," "intend," "estimate," "project" and similar expressions identify forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the SEC which can be found at www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.
On a Mission to Protect Our Planet’s Water: Seventh Generation Launches New Personal Care Line
Seventh Generation Unveils New Body Wash and Deodorant Designed to Work like you Need it to, While Protecting our Most Precious Resource
BURLINGTON, Vt., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Seventh Generation, a leading household and personal care products company and pioneer in the environmentally conscious products space, today announced the launch of Seventh Generation Not Just Body Wash⢠& Seventh Generation Not Just Deodorantâ¢, uniquely designed products on a mission to work like you need them too, and help protect our planetâs most precious resource â water.
This unique range of MADE SAFE® certified body washes and aluminum-free deodorants are not just made to help consumers stay clean and smelling fresh. The entire line is made with 100 percent Biodegradable, Water-Friendly Formulas®, designed to break down safely to reduce end of life impact and to help protect our waterways. Products are also packaged in post-consumer recycled plastic, including Ocean Bound Plastic. And, with every purchase, Seventh Generation will donate $0.25 per pack to Clean Water Action, a leading Washington D.C. based non-profit working to stop water pollution and to protect our nationâs drinking water.
âNow more than ever, itâs imperative that we take action to help preserve our planet. As a company that prioritizes the health of the next seven generations, we want to provide people with products that can help make a tangible difference without sacrificing efficacy. Weâre as excited to bring these products designed to create positive change to market as we are to be partnering with an organization such as Clean Water Action to address the broader issue of water pollution,â said Joey Bergstein, CEO of Seventh Generation.
- Seventh Generation Not Just Body Washâ¢:  Made with nourishing shea butter that helps maintain the skinâs natural moisture as it cleanses, this new body wash works like you need it to and is uniquely designed to help stop water pollution. Its packaging is made with 70 percent recycled OceanBound Plastic bottles to help remove ocean waste, and is free from parabens, dyes, sulfates, synthetic fragrances, animal testing or byproducts and formaldehyde.
- Seventh Generation Not Just Deodorantâ¢: This aluminum-free deodorant is as effective as it is uniquely designed to help stop water pollution. Packaged in 100 percent recyclable canisters made with 65 percent PCR plastic, it features a 5-ingredient odor control complex, including arrowroot powder, to deliver 24-hour odor control. As with any Seventh Generation product, there are no synthetic fragrances. Seventh Generationâs scents are made from 100 percent essential oils and botanical ingredients, leaving you feeling refreshed and ready for the day.
âToo much of our water is still not safe for fishing, swimming and drinking -- we need more action to protect sources of drinking water. We're excited to partner with Seventh Generation to make progress on some of todayâs most pressing water challenges. The company's growing market reach and role as a sustainability business leader, its aggressive commitments to reduce water and climate impacts, and its achievement of Made Safe certification for the new personal care products line add power and credibility to our work together," said Bob Wendelgass, Clean Water Action's President and CEO.
Now, we can start our morning routines like the planet depends on it. Both Not Just Deodorant⢠and Not Just Body Wash⢠are available at national retailers, including Walmart, and online. For more information on Seventh Generationâs mission and what you can do to help our water supply please visit http://www.seventhgeneration.com/cleanwateraction.
About Seventh Generation
For more than 30 years, itâs been Seventh Generationâs mission to help you protect your world with our environmentally conscious and effective household products. Our products are solutions for the air, surfaces, fabrics, pets and people within your home -- and for the community and environment outside of it. Seventh Generation offers a full line of laundry, dish and household cleaners, baby products including Free & Clear diapers, training pants and baby wipes, plus recycled paper products and recycled plastic trash bags, personal care products such as deodorant and body wash and period care products including Organic certified tampons. The company derives its name from the Great Law of the Iroquois Confederacy that states, "In our every deliberation, we must consider the impact of our decisions on the next seven generations." For information on Seventh Generation cleaning, paper, baby and feminine personal care products, to find store locations, and explore the company's website visit www.seventhgeneration.com.
About Clean Water Action
Founded in 1972, Clean Water Action is one of the nationâs leading non-profits, bringing people together to win strong health and environmental protections, focused on our water. Despite decades of cleanup progress, significant water quality challenges remain for many lakes, rivers, bays, and other vital water resources, including risks today of rollbacks that could undermine some of our most effective clean water protections. Clean Water Actionâs programs raise awareness of threats to our water -- including sources of the water we drink â and organize grassroots campaigns to restore our nationâs historic commitment to protecting clean water, now and for the future. Together with Seventh Generation, weâll make progress advancing our shared values and common goals of âfishable, swimmable, drinkable water for all.â Learn more at www.cleanwateraction.org.
About MADE SAFE
MADE SAFE®: A human-health and ecosystem focused third-party, scientific certification program that screens for known toxic chemicals in common household products. MADE SAFE uniquely employs an ecosystem evaluation approach ensuring that products do not contain known carcinogens, endocrine disruptors, reproductive toxins, neurotoxins, behavioral toxins. Additionally, the program evaluates for bioaccumulation, persistence, and environmental, terrestrial, and aquatic toxicity. MADE SAFE is a subsidiary of Nontoxic Certified, a 501(c)(3) nonprofit focused on ingredient solutions. The MADE SAFE certification makes it easy for consumers to identify products made without chemicals known or suspected to be harmful. All of Seventh Generationâs new personal care products are MADE SAFE® certified. Learn more at www.madesafe.org
Brandi Thomas
seventhgen@allisonpr.com Â
Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/57914e2f-c6b6-4035-be45-d43d991be865
https://www.globenewswire.com/NewsRoom/AttachmentNg/40b4720c-4b08-4b8e-aa0a-a78baa25a7ac
https://www.globenewswire.com/NewsRoom/AttachmentNg/a613153a-0966-4e0d-8d1f-5a0dd1c5256f
Coyote Expands CoyoteGO® Digital Freight Platform to Better Connect Shippers and Carriers On-Demand Across All Devices
Expansion includes the launch of new on-demand quote & ship features for fast, easy access to capacity
Chicago, Feb. 24, 2020 (GLOBE NEWSWIRE) -- To better connect shippers and carriers in an increasingly fragmented freight market, Coyote Logistics, a leading global third-party logistics (3PL) provider, today announced the expansion of its CoyoteGO® digital freight platform. Included in this expansion is the launch of new, on-demand features that put Coyoteâs full suite of digital solutions in one place. The result is a true end-to-end digital experience that allows shippers and carriers to keep freight moving on their terms.
âAt Coyote, our core goal is to offer the right capacity to shippers and the right freight to carriers, when and where they need it, in the most efficient way possible. The better we can achieve that through new technology innovations, the more value we can provide to both sides of the market,â said Brian Work, Chief Technology Officer, Coyote. âThe expansion of CoyoteGO® represents one of the ways weâre integrating digital solutions at critical stages throughout the shipping process, from quoting through settlement, to foster a better experience for all users.â
The CoyoteGO® digital freight platform now includes new, easy-to-use quote and ship tools that provide shippers with on-demand access to a marketplace of more than 70,000 vetted carriers to move their freight when, where and how they want. In addition to fast, easy online tendering, CoyoteGO®, accessible at go.coyote.com from desktop and mobile devices, offers shippers the following: Â
- On-demand full truckload and less than truckload (LTL) quoting and shipping
- Visibility to in-transit loads with online tracking
- A faster path to settlement with the ability to receive paperwork and invoices
- Transparency into facility ratings with almost 200,000 reviews (and growing)
For years, the CoyoteGO® app has been helping thousands of businesses grow their fleets and discover new opportunities through access to Coyoteâs network of over 10,000 loads per day. This most recent expansion builds on the success of the established carrier app and on a series of comprehensive carrier-technology enhancements made to the digital freight platform in 2019. These include last Octoberâs mobile and desktop updates, which reaffirmed why the CoyoteGO® mobile app has the highest âstickinessâ rate â the percentage of carriers who downloaded and became regular, active users â among carriers of any 3PL and brokerage platforms, according to CarrierList.
This expansion of the CoyoteGO® digital freight platform further supports our network of shippers and carriers with one centralized digital experience across all users and devices. However, Coyote maintains that technology alone is not the key to supply chain success.
âLast year, our Tech + Humanity original research study revealed that shippers and carriers agree a balance of innovative, easy-to-use technology and dedicated human support is necessary to optimally manage their supply chains,â Work said. âThe expansion of CoyoteGO® represents one of the many ways weâre delivering solutions that help achieve this balance. Weâre empowering users to ship smarter, whether through simple, on-demand access to Coyoteâs entire freight marketplace, or through a dedicated specialist that knows their business.â
Coyoteâs guiding philosophy remains the same â everything we create, regardless of end user and channel, must drive towards one simple goal: easier access to a large, diverse marketplace. With this expansion, the CoyoteGO® digital freight platform further delivers on this philosophy by offering users 24/7, on-demand access to Coyoteâs vast freight marketplace. Â
To learn more about CoyoteGO® and its latest features for shippers and carriers, or to register for a free account, please visit coyote.com.
ABOUT COYOTE LOGISTICS, LLC, A UPS COMPANY:
Coyote Logistics is a leading global third-party logistics provider that combines a diverse, centralized transportation marketplace matching more than 10,000 shipments every day. Coyote offers a comprehensive multi-modal solutions portfolioâincluding truckload, less than truckload (LTL) and intermodalâwith data intelligence and market insights to help empower our customersâ business growth in a rapidly changing world. Coyote became a UPS company in 2015, adding to our expanding portfolio of global services. Headquartered in Chicago, Coyote has more than 3,000 employees operating in 20 offices worldwide. For more information, please visit: resources.coyote.com/technology.
Join the conversation: Twitter | LinkedIn | Facebook | YouTube
Find us: #coyotelogistics #coyotenews #coyoteinsights
Rafarma Has Officially Begun Research Programs with Khon Kaen University in Thailand
Ljubljana, Slovenia, Feb. 24, 2020 (GLOBE NEWSWIRE) -- RAFARMA PHARMACEUTICALS INC. âOTC:(RAFA)â is pleased to inform its shareholders that the previously-announced specialized research project between Rafarma and Khon Kaen University officially commenced on February 19, 2020. In a meeting at the University, Rafarma discussed entering the Thai market and implemented certain changes in the research planned for the next two years. Rafarma and MTP MATERIAL CO. LTD. Have formulated a plan to begin introduction of new cannabis products and concepts for the Thai and international markets. These new products will include products developed specifically by Khon Kaen University and Rafarma utilizing the unique research facility at the University.
Rafarma expects the following key components to enhance its offering in Thailand and other Asian markets:
- Inspection and analysis of cannabis extract for compliance to standards approved by the Thai Pharmaceutical Organization will be conducted in the labs of KKU;
- The Proprietary blockchain software implementation has been scheduled for use and will allow a unique and structured tracking system from seed to sale.
- Initial installation of the first Aeroponic system will also take place on the premises of KKU.
- Once all the protocols for treatments at the specialized spa centers are developed, they will be tested and tuned at the pilot project at the KKU Medical Center. Following these tests, the protocols will be turned over for use at the first specialized spa that Rafarma plans to open in Phuket Thailand.
- Product development is expected to progress at a very fast rate using the KKU state of the art research facility. These products will be unique to Rafarma and have implementation possibilities worldwide.
âWorking to together with MTP and KKU will allow Rafarma to meet all necessary legal guidelines prior to introduction of its new products to general publicâ, Anucha Pehtpeng says.
Forward-Looking Statements: This press release contains âforward-looking statementsâ within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as âmayâ, âwillâ, âtoâ, âplanâ, âexpectâ, âbelieveâ, âanticipateâ, âintendâ, âcouldâ, âwouldâ, âestimate,â or âcontinueâ, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our managementâs beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company's filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
For more information contact:
RAFARMA
(307) 429-2029
NORBIT – Key information relating to the cash dividend to be paid by NORBIT ASA
Dividend amount: 0.60
Declared currency: NOK
Last day including right: 4 May 2020
Ex-date: 5 May 2020
Record date: 6 May 2020
Payment date: From 13 May 2020
Date of approval: 4 May 2020
For further queries, please contact:
Charlotte Knudsen, IR and Communications, +47 9756 1959
About NORBIT ASA
NORBIT is a global provider of tailored technology to carefully selected niches. The companyâs business is structured to address its key markets; Oceans, targeting the global maritime markets, Intelligent Traffic Systems (ITS), offering connectivity solutions for truck applications, and Product Innovation and Realization (PIR), with in-house multidisciplinary R&D and manufacturing.
NORBIT is headquartered in Trondheim, Norway, with manufacturing facilities in Selbu and Røros, Norway and 12 offices and subsidiaries around the world.
For more information: www.norbit.com
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Generex Congratulates their Shareholders as FINRA has Officially Posted the Approval of the Generex Corporate Action and Payment of the Generex and NuGenerex Immuno-Oncology Stock Dividends on Monday, February 24, 2020
- Dividends officially to be paid on Monday, February 24, 2020
â¢Â Shareholders to receive 2 to 5 stock dividend of Generex Biotechnology shares plus an additional 2 to 5 stock dividend of NuGenerex Immuno-Oncology shares - Ex-Date will be February 25, 2020
MIRAMAR, Fla., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (âGenerexâ) today announced that FINRA has officially posted the Generex 2:5 stock dividends in Generex and NuGenerex Immuno-Oncology to the FINRA web site, and the dividends will be paid on Monday, February 24, 2020. Remember that anyone who sells their shares before the market close on the ex-date of February 25th will lose the dividend, which will be transferred to the buyer of your shares.
Joe Moscato, President & CEO of Generex, said, âI would like to extend my congratulations and sincere thanks to our valued shareholders, because we can now officially declare that the stock dividends will be paid on Monday the 24th as FINRA has posted the approval of our corporate action on their web site. I would like to thank all of you for your patience and support of Generex throughout this process, which has delayed our plans for five months. We realize this delay has eroded share value, however, with the dividend paid, we are now we are poised for growth and success.âÂ
Mr. Moscato continued, âWith the dividend being paid next week, and our Generex S-1 registration statement filed, we can now execute fully on our plans. As a first step next week, we will be filing an S-1 for the spin out of NuGenerex Immuno-Oncology, with goal of listing directly onto the Nasdaq. With the S-1 funding, our subsidiaries can increase manufacturing, sales & marketing, and distribution of our revenue generating products. Our subsidiaries MediSource and Pantheon are already delivering sales growth of nearly 400% year over year, and we can now scale manufacturing to expand this growth. As Excellagen continues to gain approval from VAC committees in the VA system, we can expand the Olaregen sales force and implement our product line extension with Excellagen Aesthetics into the aesthetic dermatology market. We will turn on our public company MSO for orthopedic surgeons and podiatrists, and we will build NuGenerex Health in Arizona to deliver an integrated, multi-disciplinary diabetes management solution with our physician partners and continuing our efforts in diabetes, we will close on our acquisition of ALTuCELL, which is initiating human clinical trials of implanted cellular therapy using Altucaps for the treatment of Type I diabetes. We are excited about our opportunities to deliver exceptional value to our shareholders in 2020 as we achieve the success that we envisioned when we took over the company three years ago.â
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
Cautionary Note Regarding Forward-Looking Statements
This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Generex Contact:
Generex Biotechnology Corporation
Joseph Moscato
646-599-6222
Todd Falls
1-800-391-6755 Extension 222
investor@generex.com
MariMed Harvests its First Cannabis Crop in Massachusetts Amidst State-Wide Flower Shortage
NORWOOD, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- MariMed Inc. (MRMD:OTCQX) (the âCompanyâ or MariMed), a leading multi-state cannabis and hemp operator focused on health and wellness, announced today that the Company began its first cannabis harvest of 2020 at its cultivation and production facility in New Bedford, MA. This state-of-the-art cultivation and production facilityâs initial flower production is estimated to ramp up to approximately 1,000 pounds per month, including a variety of high grade cannabis from top genetic strains. MariMed operates in Massachusetts through its wholly owned, licensed subsidiary, ARL Healthcare, Inc.
In the midst of a state-wide flower shortage, MariMed received approval to start cultivation operations in November 2019. The ARL Healthcare facility contains 17 flower rooms with approximately 32,000 square feet of canopy. The Company plans to package a majority of the product for its premium flower brand, Nature's Heritage, which will be available for both the wholesale market and retail purchase at Panacea Wellness Dispensary in Middleboro, MA. The remaining product will be extracted for both edibles and raw concentrates.
âThe result of our first harvest in Massachusetts, arguably one of the fastest growing legal cannabis markets in the country, is extremely promising,â said Bob Fireman, CEO of MariMed. âMassachusetts is a key market for cannabis and with a flower shortage throughout the state, we believe operating a robust cultivation facility is crucial in ensuring that patients and consumers have access to safe, licensed cannabis rather than having to go to the black market for their wellness needs.â
Tim Shaw, MariMedâs COO, who led the Massachusetts licensing process and manages Massachusetts operations for the Company, said, âThis harvest speaks to our continued success in efficiently executing on our strategic priorities. Our goal is to continue to expand our Massachusetts cultivation capacity and retail dispensary network as the legal market continues to grow.â
âDuring this statewide flower shortage, weâre proud to provide a masterfully crafted cannabis product grown through our ultramodern horticultural processes. Natureâs Heritage is a storied brand that boasts an integrity that Massachusetts hasnât yet experienced on the legal market. The state is in for a treat,â added Jo McCarran, MariMed SVP Branding.
Massachusetts has a robust adult use market as well as a Medical Cannabis Program in which over 60,000 patients are currently enrolled. Market analysts at the Brightfield Group project the recreational cannabis market in Massachusetts will exceed $2 billion annually by 2023, with medical use growing to $125 million in the same period.
To be added to the email distribution list, please email MRMD@kcsa.com with âMRMDâ in the subject.
About MariMed:
MariMed Inc., a multi-state cannabis operator, is dedicated to improving the health and wellness of people through the use of cannabinoids and cannabis products. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units.
The Company is at the forefront of science and innovation through research developed by its lab technicians and medical advisors resulting in industry-leading products and brands, including "Kalm Fusion" and "Betty's Eddies." These precision dosed products are focused on specific medical symptoms and are licensed and distributed across the country.
In 2019, with the enactment of the 2018 US Farm Bill, MariMed formed MariMed Hemp, a wholly-owned subsidiary, to leverage its seed to sale cannabis platform and experience into the emerging hemp-based CBD industry. MariMed Hemp has developed and is marketing a portfolio of CBD brands and products to multiple retailers and direct to consumers both domestically and internationally. MariMed Hemp recently launched its Hemp Engine⢠store-within-a-store distribution platform for retailers. For additional information, visit marimedinc.com.
Important Caution Regarding Forward-Looking Statements:
This release contains certain forward-looking statements and information relating to MariMed Inc. that is based on the beliefs of MariMed Inc.'s management, as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events, including estimates and projections about its business based on certain assumptions of its management, including those described in this Release. These statements are not guarantees of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company's services and products, changes in the law and its enforcement and changes in the economic environment and developments in, and the outcome of, GenCannaâs Chapter 11 proceeding. Additional risk factors are included in the Company's public filings with the SEC. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as "hoped," "anticipated," "believed," "planned, "estimated," "preparing," "potential," "expected," "looks" or words of a similar nature. The Company does not intend to update these forward-looking statements. None of the content of any of the websites referred to herein (even if a link is provided for your convenience) is incorporated into this release and the Company assumes no responsibility for any of such content.
All trademarks and service marks are the property of their respective owners.
Company Contact
Jon Levine, CFO
MariMed Inc.
Tel (781) 559-8713
Media Contact
Jo McCarran, SVP Creative & Branding
MariMed Inc.
jmccarran@marimedinc.com
Annie Graf
KCSA Strategic Communications
agraf@kcsa.com
Investors
KCSA Strategic Communications
Scott Eckstein / Elizabeth Barker
MRMD@kcsa.comÂ
Update: Peeled Snacks Gearing Up for New Products, Market Expansion on Major Funding Announcement
Decathlon Capital Partners Makes Multimillion Dollar Investment in Natural Foods Company
CUMBERLAND, RI, Feb. 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Peeled Snacks plans to expand its product line of healthy snacks and enter new markets with the use of a major non-equity investment by Decathlon Capital Partners.
The multimillion-dollar investment will support new product development, market expansion and sales growth. Peeled Snacks is a purveyor of healthy dried fruits, vegetable crisps and other organic snacks.Â
âThe snacks consumers buy must move along a supply-chain from the farm, to our facility, to the trucking companies, to warehouses and distributors, and lastly to the store,â said CEO Jon Kalina. âWe want to make the world a better place by setting higher standards of transparency, accountability, and performance along that entire chain. In a cluttered marketplace of false advertising and profit-only business practices, we became a B Corporation to be part of the movement to redefine the role of business in our economy.â
A âB Corporationâ certification means the company meets the highest standards of verified social and environmental performance, public transparency, and legal accountability to balance profit and purpose. The certifying organization, known as B Corps, consists of corporate and social leaders driving a movement to use business as a force for good.
âWe donât just want to be the best in the world, but to be best for the world,â Kalina said. âDecathlonâs investment gives us the opportunity to pursue that goal on a global stage.â
âPeeled Snacks is well-positioned in the high-growth market for healthier snacks,â said Decathlonâs John Borchers. âTheir products are not only popular with consumers but start with fair labor policies and sustainable farming practices. Their business ethos and growth potential make us proud to invest in the Peeled Snack vision.â
About Peeled Snacks
Peeled Snacks took the mystery out of snacking and put the joy back into it. Our company started with a line of organic dried fruit that still continues to offer a whole lot of flavor without any added sugar, sulfites, preservatives, or oils. Weâre committed to creating snacks that make a positive impact on people and the environment. That means each bag of Peeled Snacks is packed with wholesome ingredients you can feel good about eating. Learn more at https://www.peeledsnacks.com.
About Decathlon Capital Partners
Decathlon Capital Partners provides growth capital for companies seeking alternatives to traditional equity investment. Through the use of highly customized revenue-based financing solutions, Decathlon provides long-term growth capital without the dilution, loss of control and operational overhead that often comes with equity-based funding. With offices in Palo Alto and Park City, Decathlon is the largest revenue-based funding investor in the U.S. and is active across a wide range of sectors. Learn more at www.decathloncapital.com.
Media Contact
Meredith Antonizio
Marketing Manager
401.437.4386 ex 108
Shawcor Announces Contract Awards for the Sangomar and Baltic Pipe Projects
TORONTO, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Shawcor Ltd. (TSX: SCL) is announcing today that its pipe coating division has entered into a contract with Subsea 7 to provide thermal insulation coating services for the Woodside Sangomar Offshore Project in Senegal. The value of the award is in the range of CAD$30-$50 million. The work is scheduled to be executed from Shawcorâs Orkanger, Norway facility commencing in the first quarter of 2021 and completing in the second quarter of 2021.
Further to its announcement in January of a letter of intent for the Baltic Pipe Project valued at approximately CAD$67 million, Shawcor is announcing that it has now entered into the definitive contract for such project.
Shawcor Ltd. is a global energy services company specializing in products and services for the pipeline and pipe services segment of the oil and gas industry and related products for the petrochemical and industrial market. The Company operates through a global network of fixed and mobile manufacturing and service facilities and is valued for its integrity, technology and proven capability to execute the most complex projects in its industry.
This news release contains forward-looking information within the meaning of applicable securities laws. Words such as "may", "will", "should", "anticipate", "plan", "expect", "believe", "predict", "estimate" or similar terminology are used to identify forward-looking information. Specifically, this news release contains forward looking information in respect of, the entering into and completion of the pipe coating contract with Europipe and the timing thereof. This forward-looking information is based on assumptions, estimates and analysis made in the light of the Company's experience and its perception of trends, current conditions and expected developments, as well as other factors that are believed by the Company to be reasonable and relevant in the circumstances. Forward-looking information involves known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from those predicted, expressed or implied by the forward-looking information and readers are cautioned not to unduly rely on forward looking information. The forward-looking information is provided as of the date of this news release and the Company does not assume any obligation to update or revise the forward-looking information to reflect new events or circumstances, except as required by law.
For further information, please contact:
Shawcor Ltd.
Paul Pierroz
Senior Vice President, Corporate & Investor Relations
Tel: 416-744-5540
Email: paul.pierroz@shawcor.com
Website: www.shawcor.com
Oxford Immunotec Schedules Fourth Quarter and Full Year 2019 Earnings Release and Conference Call for March 2, 2020
OXFORD, United Kingdom and MARLBOROUGH, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD) (the "Company"), a global, high-growth diagnostics company, today announced that it plans to release fourth quarter and full year 2019 financial results before the open of the market on Monday, March 2, 2020. Â Dr. Peter Wrighton-Smith, Chief Executive Officer, and Matt McLaughlin, Chief Financial Officer, will host a conference call to review the Company's financial results at 8:00 a.m. Eastern Time the same day. Â The call will be concurrently webcast.
To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 6733215, approximately ten minutes prior to start time. Â To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. Â The replay will be available on the Company's website for approximately 60 days.
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary assays for immunology and infectious disease.  The Company's T-SPOT®.TB test has been approved for sale in over 60 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The Company is headquartered near Oxford, U.K. and in Marlborough, MA. Additional information can be found at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
CONTACTS:
For Media and Investor Inquiries:
Matt McLaughlin
Chief Financial Officer
Oxford Immunotec
Tel: +1 (508) 573-9953
mtmclaughlin@oxfordimmunotec.com
Telos Corporation Nationally Designated as One of the Best Workplaces for Commuters in 2020
Telos among select group of U.S. companies recognized for offering employees exceptional commuter benefits and reducing environmental impact.
ASHBURN, Va., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Telos ® Corporation, a leading provider of cyber, cloud and enterprise security solutions for the worldâs most security-conscious organizations, has been named one of the 2020 Best Workplaces for Commuters for offering employees exceptional commuter benefits.
Telos is among a select group of workplaces in the United States that have achieved the Best Workplaces for Commuters National Standard of Excellence by providing an array of commuter benefits, resulting in at least 14 percent of their employee base not driving alone to work within a 12-month period. Telos offers employees several commuter benefit options, including: Â
- Teleworking program, which reduced the number of commuting trips employees took per week by at least 6 percent,
- Compressed work schedules that reduced overall employee commuting trips, and
- Secure bicycle parking at Telos headquarters, and on site showers and lockers accessible to employees who walk or bike to the workplace.
âTelos Corporation is one of the top employers in the nation offering high level commuter benefits to their employees,â said Julie Bond, program manager, Best Workplaces for Commuters. âTelos made the list because they offer transportation choices that include a teleworking program and the option of a compressed work week. Telos gives its employees the support they need to get to and from work and be at their best before, during, and after their workday.â
âWe take immense pride in receiving our 2020 Best Workplaces for Commuters national designation,â said Shelley Trask, vice president of human resources, Telos. Â âOur benefits give us a competitive edge in employee recruitment and retention while helping reduce traffic congestion and negative environmental impact.â
The Best Workplaces for Commuters program offers designated organizations access to a range of support services to assess and promote non-driving commuting of employees, including organizational assessment and implementation tool-kits, web-based tools and webinars, staff training, and information exchange.
To learn more about a career at Telos, visit: www.telos.com/careersÂ
About Telos Corporation
Telos Corporation empowers and protects the worldâs most security-conscious organizations with solutions for continuous security assurance of individuals, systems, and information. Telosâ offerings include cybersecurity solutions for IT risk management and information security; cloud security solutions to protect cloud-based assets and enable continuous compliance with industry and government security standards; and enterprise security solutions to ensure that personnel can work and collaborate securely and productively. The company serves military, intelligence and civilian agencies of the federal government, allied nations and commercial organizations around the world. The company is a recipient of the prestigious James S. Cogswell Outstanding Industrial Security Achievement Award from the Defense Security Service (DSS), awarded to less than .03% of eligible organizations. For more information, visit www.telos.com and follow the company on Twitter @TelosNews
About Best Workplaces for Commuters
Best Workplaces for Commuters is the national authority on recognizing and assisting workplaces that provide exceptional commuter benefits to employees. More than a recognition program, the Best Workplaces for Commuters program provides support needed to create and sustain an employer-provided commuter benefit program, including online assessment tools, advisory services, case studies, tool-kits, web-based tools, webinars and training. Best Workplaces for Commuters represents over 350 workplaces with Best Workplaces for Commuters designation representing over 2,000,000 employees. The Best Workplaces for Commuters program is managed by the Center for Urban Transportation Research (CUTR)Â at the University of South Florida with support from the Florida Department of Transportation (FDOT).
Contact:
Allison Phillipp
Telos Corporation
Email: Allison.phillipp@telos.com Â
Phone: 703.724.3642
Alliance Trust PLC - Net Asset Value
ALLIANCE TRUST PLC
                                 Â
At the close of business Friday 21 February 2020:
The Companyâs NAV per ordinary share, valued on a bid price basis with Debt at Par, was
-Â Â Â Â Â Â excluding income, 912.1p
-Â Â Â Â Â Â including income, 916.4p
 Â
The Companyâs NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was
-Â Â Â Â Â Â excluding income, 898.4p
-Â Â Â Â Â Â including income, 902.7p
For further information, please contact: -
| Â |
| Alliance Trust PLC |
| Tel. +44 (0)1382 938320 |
Notes
- Net Asset Values are calculated in accordance with published accounting policies and AIC guidelines.
- The fair value of the Companyâs fixed loan notes is calculated by reference to a benchmark gilt.
Middlefield Canadian Income PCC: Net Asset Value(s)
Middlefield Canadian Income PCC Net Asset Value
Middlefield Canadian Income PCC
Middlefield Canadian Income - GBP PC
(a protected cell company incorporated in Jersey with registration number 93546)
Legal Entity Identifier: 2138007ENW3JEJXC8658
Net Asset Value
As at the close of business on 21 February 2020 the estimated unaudited Net Asset Value per share was 122.80 pence (including accrued income).
Investments in the Companyâs portfolio have been valued on a closing price basis.
Enquiries:
JTC Fund Solutions (Jersey) Limited
01534 700 000
ClearOne Seeks Order Holding Shure in Contempt for Marketing and Selling the MXA910W-A in Violation of 2019 Preliminary Injunction
SALT LAKE CITY, Feb. 24, 2020 (GLOBE NEWSWIRE) --  ClearOne (NASDAQ: CLRO), a leading global provider of audio and visual communication solutions, on February 21, 2020, asked for a Court order that Shure has been manufacturing, marketing, and selling its redesigned MXA910, the MXA910W-A released in December 2019, in violation of a preliminary injunction issued by Judge Edmond E. Chang of the U.S. District Court of the Northern District of Illinois. That court-ordered injunction prohibits Shure from âmanufacturing, marketing, and sellingâ the MXA910 for use âin its drop-ceiling mounting configuration, including marketing and selling the MXA910 in a way that encourages or allows integrators to install it in a drop-ceiling mounting configuration.â By law, the injunction applies to the MXA910 and âcolorable imitationsâ thereof.
ClearOneâs filing asserts that Shure has been willfully manufacturing, marketing, and selling its MXA910W-A in a way that âencourages or allows integrators to install it in a drop-ceiling mounting configuration.â The measurements of the MXA910W-A allow it to be installed securely in the prohibited configuration in the majority of U.S. drop-ceiling grids, and Shureâs marketing materials encourage such installation.  In addition, ClearOne has found evidence that third parties are in fact installing the MXA910W-A in the prohibited configuration. ClearOne has asked the Court to order Shure to cease marketing and selling the MXA910W-A in the United States, notify all customers that the MXA910W-A violates the preliminary injunction and is thus subject to recall, award ClearOne its attorneysâ fees associated with the contempt motion, and for additional discovery relating to how Shureâs customers are installing the MXA910W-A.
âShure chose to play fast and loose with the Courtâs preliminary injunction order, rushing to market with a design that, we believe, still infringes ClearOneâs patent,â said Zee Hakimoglu, ClearOne Chair and CEO. âShure appears to have fully appreciated the risks they were taking, yet they willingly crossed the line, making things more difficult for all involved.â Ms. Hakimoglu reiterated that âClearOne remains committed to protecting its intellectual property rights while playing by the rules, and wonât be intimidated by Shure into foregoing ClearOneâs right to fair competition on a level playing field.â Â
The case number in the U.S. District Court of the Northern District of Illinois is 17-cv-3078.
About ClearOne
ClearOne is a global company that designs, develops, and sells conferencing, collaboration, and network streaming solutions for voice and visual communications. The performance and simplicity of its advanced, comprehensive solutions offer unprecedented levels of functionality, reliability and scalability. Visit ClearOne at www.clearone.com.
Printable releases are available in our Investor Relations area at http://investors.clearone.com.
Capital Market Laboratories (CMLviz) Interviews Talend (TLND) CEO and CFO – ‘The opportunity is massive, and we want to get it right’
LOS ANGELES, Feb. 24, 2020 (GLOBE NEWSWIRE) -- In an interview with Capital Market Laboratories (CMLviz), chief executive officer of Talend SA (NASDAQ:TLND) Christal Bemont had a few clear messages:Â
- She aims to drive growth with a âwell-oiled machineâ to turn things around.
- The opportunity is massive, and she wants to get it right.
- Cloud annual recurring revenue is the most important way to measure the companyâs success and growth and was up 179% year-over-year.
In a far-ranging interview with Talendâs CEO and CFO we discussed the future of the business.
Read: Talend CEO Bemont Aims to Drive Growth With a âWell-oiled Machineâ
Media queries
Alicia Newman, Director Client Services
Capital Market Laboratories
ORYZON Reports Financial Results and Corporate Update for 4th Quarter and Year Ended December 31, 2019
MADRID, Spain and CAMBRIDGE, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reports financial results for the fourth quarter of 2019 and provides an update on recent developments.
"Oryzon continued to make strong clinical progress in the fourth quarter,â said Dr. Carlos Buesa, Oryzonâs Chief Executive Officer. âWe are encouraged by the promising efficacy seen in both our iadademstat oncology program and vafidemstat neurology program and importantly, these exciting signals of clinical activity were achieved with good safety and tolerability profiles. We look forward to a number of important milestones in 2020, including data readouts for our REIMAGING-AD and ETHERAL trials and the initiation of the Phase IIb PORTICO study evaluating vafidemstat in borderline personality disorder and also additional data on the ongoing cancer trials. We are confident that our two lead candidates are exciting potential treatment options in areas of high unmet medical need and look forward to continued clinical progress.â
Fourth Quarter and Recent Highlights
Iadademstat in oncology:
- New positive efficacy data from Phase II trial ALICE, investigating iadademstat in acute myeloid leukemia (AML) at the 61st ASH Annual Meeting and Exposition in Orlando, United States.
- Reported objective responses in 6 out of 8 evaluable patients (75% OR): of these, there were 2 complete remissions (CR), 3 complete remissions with incomplete hematologic recovery (CRi) and 1 partial remission (PR).
- The mean follow-up time amongst the evaluable patients was 20 weeks, with a mean Time to Response (TTR) of only 32 days in those patients who responded.
- Two of the 5 patients (40%) that had received more than 3 cycles of treatment had also become transfusion independent.
- Encouraging preliminary efficacy data from the first 8 patients in the CLEPSIDRA Phase II trial evaluating the safety and clinical efficacy of iadademstat in combination with platinum/etoposide in second-line small cell lung cancer (SCLC) patients at the ESMO conference in Barcelona.
- Reported responses in 6 out of 8 patients (75% response rate), with 4 partial remissions and 2 long-term disease stabilizations in patients treated with iadademstat plus carboplatin/etoposide.
- Demonstrated durable treatment response with one partial remission patient at cycle 13 and still in response. This patient showed an initial 78.7% tumor reduction as determined by RECIST after 6 cycles of iadademstat plus carboplatin/etoposide. Tumor reduction continued upon iadademstat monotherapy after the combo cycles, with 86.3% of tumor reduction by RECIST at the end of cycle 12.
- The clinical trial continues to recruit patients and investigate dosing regimens to minimize hematological toxicity of the combination.
Vafidemstat in neurological disease:
- Additional positive Phase IIa REIMAGINE efficacy data of vafidemstat in the treatment of aggression in three psychiatric diseases at the 2019 International College of Neuropsychopharmacology (CINP) meeting in Athens, Greece.
- Reported data from ADHD, BDP and ASD and aggregated cohorts demonstrating statistically significant improvements in several scales measuring aggression such as the Clinical Global Impression (CGI) of Severity (CGI-S) and Improvement (CGI-I) scales and the Neuropsychiatric Inventory (NPI) 4-item Agitation/Aggression subscale.
- Benefits also observed on several scales more generally assessing the global condition of the patients, such as the Neuropsychiatric Inventory (NPI) total score, the global BPD checklist (BPDCL) scale (for BPD patients) and the ADHD Rating Scale (ADHD-RS) (for ADHD patients).
- On the strength of these data, the company is currently preparing a Phase IIb trial in BPD (PORTICO trial), expected to start in 1H2020, and is evaluating additional Phase IIb studies in ADHD and/or ASD.
- The company has completed the recruitment in REIMAGINE-AD, a Phase IIa trial evaluating the effect of vafidemstat to treat aggressiveness in moderate and severe Alzheimer's disease (AD) with a total of 12 patients. The company plans to report the results of this study at the AAT-AD/PD conference in April 2020 in Vienna, Austria.
- The company has completed recruitment of the Phase IIa ETHERAL trial in Europe, with 117 patients randomized, while it continues in the parallel US arm (ETHERAL-US). ETHERAL is a randomized, double-blind, 3-arm, parallel-group study with a 24-week placebo-controlled period followed by a 24-week extension in which placebo patients are randomized to vafidemstat therapy, to evaluate the safety, tolerability and preliminary efficacy of vafidemstat in patients with mild to moderate AD. Positive safety data from the first 104 patients in ETHERAL were presented at the 2019 Alzheimer's Association International Conference (AAIC-2019) in Los Angeles and the company plans to present initial interim 6-month treatment data from the EU trial also at the AAT-AD/PD conference in April 2020.
- The company announced that the extension phase of the SATEEN Phase IIa clinical trial evaluating vafidemstat in multiple sclerosis has been extended in patients with the secondary progressive form of the disease up to a maximum of 18 months of vafidemstat treatment. This extension will allow the assessment of the effect of vafidemstat as a therapeutic treatment for the progressive form of the disease which requires longer clinical observation periods.
Financial Update: Fourth Quarter 2019 Financial Results
Research and development (R&D) expenses were $3.6 and $12.7 million, respectively, for the 3 and 12 months ended December 31, 2019 compared to the $2.3 and $8.5 million for the 3 and 12 months ended December 31, 2018. The $4.2 million increase was driven primarily by expenses associated with advancing the companyâs clinical trials.
General and administrative expenses were $0.5 and $3.2 million, respectively, for the 3 and 12 months ended December 31, 2019 compared to $0.5 and $3.0 million for the 3 and 12 months ended December 2018.
Net losses were $0.8 and $4.3 million, respectively, for the 3 and 12 months ended December 31, 2019, compared to net losses of $0.7 and $3.3 million for the 3 and 12 months ended December 2018.
Negative net result of $4.1 million (-$0.10 per share) for the 12 months ended December 31, 2019 as a consequence basically of -$1.7 million non-recurrent R&D tax deductions, compared to a negative net result of $1.3 million for the 12 months ended December 31, 2018.
Cash, cash equivalents and marketable securities totaled $39.6 million as of December 31, 2019, compared to $39.5 million as of December 31, 2018.
| Â | Â | Â | Â | Â | Â |
| ORYZON GENOMICS SA | |||||
| BALANCE SHEET DATA (AUDITED)1 | |||||
| (Amounts in thousands US $) | |||||
| Â | Â | Â | Â | Â | Â |
| Â | Â | December 31st, 2019 | Â | December 31st, 2018 | Â |
| Â | Â | Â | Â | Â | Â |
| Â | Cash and cash equivalents | 39,430 | Â | 39,296 | Â |
| Â | Marketable securities | 159 | Â | 162 | Â |
| Â | Total Assets | 89,946 | Â | 77,231 | Â |
| Â | Â | Â | Â | Â | Â |
| Â | Deferred revenue | 0 | Â | 0 | Â |
| Â | Total Stockholders' equity | 68,648 | Â | 51,668 | Â |
| Â | Â | Â | Â | Â | Â |
| Â | ORYZON GENOMICS SA | ||||||
| Â | STATEMENTS OF OPERATIONS (AUDITED)1 | ||||||
| Â | (US $, amounts in thousands except per share data) | ||||||
| Â | Â | Â | Â | Â | Â | Â | Â |
| Â | Â | Â | Three Months Ended December 31st | Â | Twelve Months Ended December 31st | ||
| Â | Â | Â | Â | ||||
| Â | Â | Â | 2019 | 2018 | Â | 2019 | 2018 |
| Â | Â | Â | Â | Â | Â | Â | Â |
| Â | Collaboration Revenue | 0 | 0 | Â | 0 | 0 | |
| Â | Â | Â | Â | Â | Â | Â | Â |
| Â | Operating expenses: | Â | Â | Â | Â | Â | |
| Â | Research and Development | 3,553 | 2,324 | Â | 12,715 | 8,489 | |
| Â | General and administrative | 516 | 539 | Â | 3,185 | 2,993 | |
| Â | Â | Â | Â | Â | Â | Â | Â |
| Â | Total operating expenses | 4,069 | 2,863 | Â | 15,900 | 11,482 | |
| Â | Â | Â | Â | Â | Â | Â | Â |
| Â | Loss from Operations | -4,069 | -2,863 | Â | -15,900 | -11,482 | |
| Â | Â | Â | Â | Â | Â | Â | Â |
| Â | Other income, net | 3,301 | 2,177 | Â | 11,589 | 8,143 | |
| Â | Â | Â | Â | Â | Â | Â | Â |
| Â | Net Loss | Â | -768 | -686 | Â | -4,312 | -3,339 |
| Â | Â | Â | Â | Â | Â | Â | Â |
| Â | Net Financial & Tax | -296 | -178 | Â | 174 | 1,991 | |
| Â | Â | Â | Â | Â | Â | Â | Â |
| Â | Net Result | Â | -1,064 | -864 | Â | -4,138 | -1,348 |
| Â | Â | Â | Â | Â | Â | Â | Â |
| Â | Â | Â | Â | Â | Â | Â | Â |
| Â | Loss / profit per share allocable to common stockholders: | Â | Â | Â | |||
| Â | Basic | Â | -0.02 | -0.02 | Â | -0.10 | -0.04 |
| Â | Diluted | Â | -0.02 | -0.02 | Â | -0.10 | -0.04 |
| Â | Â | Â | Â | Â | Â | Â | Â |
| Â | Weighted average Shares outstanding | Â | Â | Â | Â | ||
| Â | Basic | Â | 45,488,554 | 36,836,648 | Â | 41,589,158 | 34,335,636 |
| Â | Diluted | Â | 45,488,554 | 36,836,648 | Â | 41,589,158 | 34,335,636 |
| Â | Â | Â | Â | Â | Â | Â | Â |
| Â | 1 Spanish GAAP | Â | Â | Â | Â | Â | Â |
| Â | * Exchange Euro/Dollar (1.123 for 2019 and 1.145 in 2018) | Â | Â | Â | |||
| Â | Â | Â | Â | Â | |||
About Oryzon
Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. Oryzon has one of the strongest portfolios in the field. Oryzonâs LSD1 program has rendered two compounds, vafidemstat and iadademstat, in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon has offices in Spain and the United States. For more information, visit www.oryzon.com
FORWARD-LOOKING STATEMENTS
This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words âexpects,â âanticipates,â âbelieves,â âintends,â âestimatesâ and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forwardâlooking statements, whether as a result of new information, future events or otherwise. This press release is not an offer of securities for sale in the United States or any other jurisdiction. Oryzonâs securities may not be offered or sold in the United States absent registration or an exemption from registration. Any public offering of Oryzonâs securities to be made in the United States will be made by means of a prospectus that may be obtained from Oryzon or the selling security holder, as applicable, that will contain detailed information about Oryzon and management, as well as financial statements.
| IR & Media, US & Europe: | Spain: | Oryzon: |
| LifeSci Advisors LLC | ATREVIA | Emili Torrell |
| Hans Herklots | Patricia Cobo/Idoia Revuelta | BD Director |
| +41 79 598 7149 | +34 91 564 07 25 | +34 93 515 13 13 |
| hherklots@lifesciadvisors.com | pcobo@atrevia.com irevuelta@atrevia.com | etorrell@oryzon.com |
Â
